Patents by Inventor James Janetka

James Janetka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Small molecule regulators of mitochondrial fusion and methods of use thereof
    Patent number: 10844023
    Abstract: Compositions comprising small molecule mitofusin agonists are described. The mitofusin modulating agents are useful for treating diseases or disorders associated with a mitochondria-associated disease, disorder, or condition such as diseases or disorders associated with mitofusin 1 (Mfn1) and/or mitofusin 2 (Mfn2), or mitochondrial dysfunction. Methods of treatment, pharmaceutical formulations, and screening methods for identifying compounds that regulate mitochondrial function are also described.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: November 24, 2020
    Assignee: WASHINGTON UNIVERSITY
    Inventors: Gerald W. Dorn, II, James Janetka
  • SMALL MOLECULE REGULATORS OF MITOCHONDRIAL FUSION AND METHODS OF USE THEREOF
    Publication number: 20190169138
    Abstract: Compositions comprising small molecule mitofusin agonists are described. The mitofusin modulating agents are useful for treating diseases or disorders associated with a mitochondria-associated disease, disorder, or condition such as diseases or disorders associated with mitofusin 1 (Mfn1) and/or mitofusin 2 (Mfn2), or mitochondrial dysfunction. Methods of treatment, pharmaceutical formulations, and screening methods for identifying compounds that regulate mitochondrial function are also described.
    Type: Application
    Filed: October 4, 2018
    Publication date: June 6, 2019
    Inventors: Gerald W. Dorn, II, James Janetka
  • HETEROCYCLIC AMIDES USEFUL FOR THE TREATMENT OF CANCER AND PSORIASIS
    Publication number: 20100311748
    Abstract: The present disclosure relates to heterocyclic amide compounds, which are useful for inhibiting the Hedgehog pathway, and their use in treating a disease or medical condition mediated alone or in part by Hedgehog pathway inhibition. Also disclosed are methods for manufacture of these compounds, pharmaceutical compositions including these compounds, and use of these compounds in the manufacture of medicaments for treating such diseases and medical conditions in a subject. Formula (IA) with the provisio that either R2 or R3 is (Z).
    Type: Application
    Filed: August 29, 2008
    Publication date: December 9, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Leslie Dakin, Benjamin Fauber, Alexander Hird, James Janetka, Daniel John Russell, Qibin Su, Bin Yang, Xiaolan Zheng
  • SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS
    Publication number: 20090275570
    Abstract: The invention relates to novel compounds of Formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds possess CHK1 kinase inhibitory activity, PDK1 inhibitory activity and Pak kinase inhibitory activity and are accordingly useful in the treatment and/or prophylaxis of cancer.
    Type: Application
    Filed: April 5, 2006
    Publication date: November 5, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Kevin Daly, Nicola Heron, Alexander Hird, Stephanos Ioannidis, James Janetka, Paul Lyne, Jaime Scott, Dorin Toader, Melissa Vasbinder, Dingwei Yu, Yan Yu
  • SUBSTITUTED THIOPHENES AND USES THEREOF
    Publication number: 20090054396
    Abstract: This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cancer.
    Type: Application
    Filed: September 8, 2008
    Publication date: February 26, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Susan Ashwell, Thomas Gero, Stephanos Ioannidis, James Janetka, Paul Lyne, Vibha Oza, Mei Su, Dingwei Yu, Stephanie Springer
  • Substitute thiophenes and uses thereof
    Patent number: 7423061
    Abstract: This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cancer.
    Type: Grant
    Filed: August 12, 2004
    Date of Patent: September 9, 2008
    Assignee: AstraZeneca AB
    Inventors: Susan Ashwell, Thomas Gero, Stephanos Ioannidis, James Janetka, Paul Lyne, Vibha Oza, Stephanie Springer, Mei Su, Dingwei Yu
  • Thiophene derivatives as chk 1 inhibitors
    Publication number: 20070010556
    Abstract: This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of cancer.
    Type: Application
    Filed: December 24, 2004
    Publication date: January 11, 2007
    Applicant: ASTRAZENECA AB
    Inventors: Susan Ashwell, Thomas Gero, Stephanos Ioannidis, James Janetka, Paul Lyne, Su Mei, Doria Toader, Dingwei Yu, Yan Yu
  • Substitute thiophenes and uses therof
    Publication number: 20060281666
    Abstract: This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cancer.
    Type: Application
    Filed: August 12, 2004
    Publication date: December 14, 2006
    Inventors: Susan Ashwell, Thomas Gero, Stephanos Ioannidis, James Janetka, Paul Lyne, Vibha Oza, Stephanie Springer, Mei Su, Dingwei Yu
  • Pyrazole compositions useful as inhibitors of erk
    Patent number: 7056944
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: where R1-4, Q, and T are described in the specification. The compounds are useful for treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.
    Type: Grant
    Filed: October 17, 2003
    Date of Patent: June 6, 2006
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Michael Hale, Xiaoling Xie, Jeremy Green, Jingrong Cao, Christopher Baker, Francois Maltais, James Janetka, Guy Bemis, Michael Mullican, Judith Straub, Qing Tang, Robert Mashal
  • Pyrazole-derived kinase inhibitors and uses thereof
    Publication number: 20050215550
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: where B, R1, n, R3, Q, and R4 are described in the specification. The compounds are useful for treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.
    Type: Application
    Filed: January 5, 2005
    Publication date: September 29, 2005
    Inventors: Oing Tang, Francois Maltais, James Janetka, Michael Hale
  • Pyrazole compositions useful as inhibitors of ERK
    Patent number: 6949580
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: where R1, R2, T and Ht are described in the specification. The compounds are useful for treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.
    Type: Grant
    Filed: October 16, 2003
    Date of Patent: September 27, 2005
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Michael Hale, James Janetka, Francois Maltais
  • Isoxazole compositions useful as inhibitors of ERK
    Publication number: 20050090536
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors, especially inhibitors of ERK, having the formula: where A, B, R1, R2, T and Ht are described in the specification. The compounds are useful for treating diseases in mammals that are alleviated by a protein, kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.
    Type: Application
    Filed: July 24, 2003
    Publication date: April 28, 2005
    Inventors: Michael Hale, James Janetka, Francois Maltais, Jingrong Cao, Robert Mashal
  • Pyrazole compositions useful as inhibitors of ERK
    Patent number: 6784195
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: where R1, R2, T and Ht are described in the specification. The compounds are useful for treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.
    Type: Grant
    Filed: October 5, 2001
    Date of Patent: August 31, 2004
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Michael Hale, James Janetka, Francois Maltais, Jingrong Cao
  • Pyrazole compositions useful as inhibitors of ERK
    Publication number: 20040102506
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: 1
    Type: Application
    Filed: October 17, 2003
    Publication date: May 27, 2004
    Inventors: Michael Hale, Xiaoling Xie, Jeremy Green, Jingrong Cao, Christopher Baker, Francois Maltais, James Janetka, Guy Bemis, Michael Mullican, Judith Straub, Qing Tang, Robert Mashal
  • Pyrazole compositions useful as inhibitors of ERK
    Publication number: 20040082631
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: 1
    Type: Application
    Filed: October 16, 2003
    Publication date: April 29, 2004
    Inventors: Michael Hale, James Janetka, Francois Maltais
  • Pyrazole compositions useful as inhibitors of ERK
    Patent number: 6699865
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: where R1-4, Q, and T are described in the specification. The compounds are useful for treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.
    Type: Grant
    Filed: January 2, 2003
    Date of Patent: March 2, 2004
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Michael Hale, Xiaoling Xie, Jeremy Green, Jingrong Cao, Christopher Baker, Francois Maltais, James Janetka, Guy Bemis, Michael Mullican, Judith Straub, Qing Tang
  • Pyrazole compositions useful as inhibitors of ERK
    Publication number: 20030225151
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: 1
    Type: Application
    Filed: January 2, 2003
    Publication date: December 4, 2003
    Inventors: Michael Hale, Xiaoling Xie, Jeremy Green, Jingrong Cao, Christopher Baker, Francois Maltais, James Janetka, Guy Bemis, Michael Mullican, Judith Straub, Qing Tang
  • Isoxazole compositions useful as inhibitors of ERK
    Patent number: 6649640
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors, especially inhibitors of ERK, having the formula: where A, B, R1, R2, T and Ht are described in the specification. The compounds are useful for treating diseases in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.
    Type: Grant
    Filed: October 15, 2002
    Date of Patent: November 18, 2003
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Michael Hale, James Janetka, Francois Maltais, Jingrong Cao
  • Isoxazole compositions useful as inhibitors of ERK
    Publication number: 20030195241
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors, especially inhibitors of ERK, having the formula: 1
    Type: Application
    Filed: October 15, 2002
    Publication date: October 16, 2003
    Inventors: Michael Hale, James Janetka, Francois Maltais, Jingrong Cao, Robert Mashal
  • Pyrazole compositions useful as inhibitors of ERK
    Patent number: 6593357
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: where R1-4, Q, and T are described in the specification. The compounds are useful for treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.
    Type: Grant
    Filed: August 22, 2002
    Date of Patent: July 15, 2003
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jeremy Green, Jingrong Cao, Michael Hale, Christopher Baker, Francois Maltais, James Janetka, Michael Mullican, Guy Bemis, Xiaoling Xie, Judith Straub, Qing Tang